CRISPR THERAPEUTICS AG (CRSP)       62.8  -0.36 (-0.57%)

62.8  -0.36 (-0.57%)

CH0334081137 - Common Stock

News Image
2 days ago - Investor's Business Daily

S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market

Eli Lilly leads medical stocks setting up and showing relative strength.

News Image
10 days ago - Investor's Business Daily

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

News Image
10 days ago - MarketBeat

No One Told These 3 Stocks It’s a Down Week

At the individual stock level, there have been some interesting contrarian movers, especially in the electric vehicle (EV) space.

News Image
11 days ago - Investor's Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

News Image
23 days ago - Investor's Business Daily

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine Biosciences leads five medical stocks showing resilience.

News Image
a month ago - CRISPR Therapeutics AG

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...

News Image
a month ago - InvestorPlace

5 Top Stocks Cathie Wood Is Selling This Week

Cathie Wood and her flagship ETF ARKK received $54.2 million of inflows earlier this month. Here's what she's selling.

News Image
a month ago - InvestorPlace

5 Cathie Wood Stocks Signaling “The Bear Market Is Over”

These top Cathie Wood stocks are signalling that the bear market is over. For savvy investors, that presents a chance to profit.

News Image
2 months ago - CRISPR Therapeutics AG

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

-CLIMB-111 and CLIMB-121 fully enrolled; completed regulatory discussions for exagamglogene autotemcel (exa-cel), formerly known as CTX001™, with the...

News Image
2 months ago - MarketBeat

MarketBeat: Week in Review 8/1 - 8/5

The hot jobs report is dispelling any notion that interest rates will level off. But the market moves on and here are some of the stocks and stories to follow.

News Image
2 months ago - Investor's Business Daily

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion

Shares of Pfizer's rumored takeover target have rocketed for two days running.

News Image
2 months ago - InvestorPlace

Why Are Gene Editing Stocks NTLA, ALNY, CRSP, BEAM Up Today?

Gene editing stocks are a bright spot on the market today after Alnylam announced the success of one of its RNAi therapies, Patisiran.

News Image
2 months ago - MarketBeat

Could CRISPR Therapeutics be a Moonshot Hiding in Plain Sight?

This article reviews the current state of affairs for CRISPR Therapeutics so you can decide if the gene editing company is worth a speculative investment

News Image
2 months ago - InvestorPlace

Will a Recession Cause a Housing Crash in 2022?

For stock investors looking for real estate exposure, the market dislocation also provides many once-a-decade deals.

News Image
2 months ago - InvestorPlace

7 Undervalued Biotech Stocks to Buy Before They Boom

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.